Turnstone Biologics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-74.9	-55.24	-31.02	3.48
Depreciation & Amortization	2.6	2.8	3.9	2.01
Share-Based Compensation	4.27	4.22	4.37	2.61
Other Operating Activities	1.59	-17.97	-48.5	-83.52
Operating Cash Flow	-66.44	-66.15	-71.06	-45.63
Capital Expenditures	-0.19	-0.8	-5.17	-3.41
Change in Investments	-30.31	-27.3	-9.76	0.06
Investing Cash Flow	-30.5	-28.09	-14.93	-3.35
Share Issuance / Repurchase	77.86	77.94	0.16	0.34
Other Financing Activities	-	-0.9	-2.81	79.62
Financing Cash Flow	77.86	77.05	-2.66	79.95
Net Cash Flow	-19.08	-17.2	-88.65	30.98
Free Cash Flow	-66.63	-66.95	-76.23	-49.04
Free Cash Flow Margin	-	-346.78%	-104.00%	-48.41%
Free Cash Flow Per Share	-2.90	-5.79	-30.68	-2.86

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).